These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 4290035)

  • 41. Improved protocols for histamine sensitization testing of acellular pertussis vaccines.
    Oh H; Joung J; Kim BG; Nam KT; Hong SH; Song HC; Lee HL; Ahn BY
    Vaccine; 2012 Nov; 30(50):7246-52. PubMed ID: 23084771
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A curious histamine-sensitizing activity shown by the newly-developed Japanese acellular pertussis vaccine.
    Iwasa S; Ishida S; Asakawa S; Akama K
    Dev Biol Stand; 1985; 61():453-60. PubMed ID: 3835082
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pertussis toxin-induced histamine sensitisation: an aspecific phenomenon independent from the nitric oxide system?
    van Meijeren CE; Vleeming W; van de Kuil T; Gerards AL; Hendriksen CF; de Wildt DJ
    Eur J Pharmacol; 2004 Jun; 493(1-3):139-50. PubMed ID: 15189775
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A new biological assay method for histamine-sensitizing factor using survival time as a response.
    Ishida S; Kurokawa M; Asakawa S
    Jpn J Med Sci Biol; 1976 Jun; 29(3):139-50. PubMed ID: 978834
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pertussis antigens--screening models on toxicity.
    Ronneberger H; Blackkolb F; Guthöhrlein G
    Arch Toxicol Suppl; 1982; 5():129-32. PubMed ID: 6285854
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interconnexion between the protective antigen and the histamine-sensitizing factor of Bordetella pertussis.
    JOO I; PUSZTAI Z
    Nature; 1960 Oct; 188():331-2. PubMed ID: 13790658
    [No Abstract]   [Full Text] [Related]  

  • 47. Comparison of 13 acellular pertussis vaccines: overview and serologic response.
    Edwards KM; Meade BD; Decker MD; Reed GF; Rennels MB; Steinhoff MC; Anderson EL; Englund JA; Pichichero ME; Deloria MA
    Pediatrics; 1995 Sep; 96(3 Pt 2):548-57. PubMed ID: 7659475
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of Adenylate Cyclase Toxoid Antigen in Acellular Pertussis Vaccines by Using a Bordetella pertussis Challenge Model in Mice.
    Boehm DT; Hall JM; Wong TY; DiVenere AM; Sen-Kilic E; Bevere JR; Bradford SD; Blackwood CB; Elkins CM; DeRoos KA; Gray MC; Cooper CG; Varney ME; Maynard JA; Hewlett EL; Barbier M; Damron FH
    Infect Immun; 2018 Oct; 86(10):. PubMed ID: 30012638
    [No Abstract]   [Full Text] [Related]  

  • 49. [Immunobiological properties of Bordetella pertussis].
    Kopacka B
    Pediatr Pol; 1972; 47(3):361-70. PubMed ID: 4336329
    [No Abstract]   [Full Text] [Related]  

  • 50. [Bordetella pertussis spheroplasts. 4. The protective, histamine-sensitizing and toxic action of spheroplasts and spheroplast cell walls].
    Milleck J; Ocklitz HW
    Zentralbl Bakteriol Orig A; 1972 Mar; 219(3):358-65. PubMed ID: 4122376
    [No Abstract]   [Full Text] [Related]  

  • 51. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques.
    Gupta RK; Saxena SN; Sharma SB; Ahuja S
    Dev Biol Stand; 1991; 73():205-22. PubMed ID: 1778314
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Histamine-sensitizing activity of various pertussis vaccines.
    JOO I; PUSZTAI Z; JUHASZ VP
    Z Immun exp ther; 1961 Mar; 121():143-58. PubMed ID: 13790657
    [No Abstract]   [Full Text] [Related]  

  • 53. Studies on the histamine-sensitizing factor of Bordetella pertussis by density gradient centrifugation.
    Griffiths BW; Mason MA
    Can J Microbiol; 1968 May; 14(5):525-8. PubMed ID: 4173097
    [No Abstract]   [Full Text] [Related]  

  • 54. Effect of histamine on lung cyclic AMP levels in normal and pertussis-vaccinated mice.
    Ortez RA
    Biochem Pharmacol; 1976 Mar; 25(5):523-6. PubMed ID: 182175
    [No Abstract]   [Full Text] [Related]  

  • 55. Enhancement of reaginic and hemagglutinating antibody production by an extract of Bordetella pertussis containing histamine sensitizing factor.
    Lehrer SB; Vaughn JH; Tan EM
    J Immunol; 1976 Jan; 116(1):178-83. PubMed ID: 173756
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunologic and biochemical properties of the histamine-sensitizing factor from Bordetella pertussis.
    Lehrer SB; Vaughan JH; Tan EM
    J Immunol; 1975 Jan; 114(1 Pt 1):34-9. PubMed ID: 46244
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Toxic factors of Bordetella pertussis, with special reference to leukocytosis-promoting factor, histamine-sensitizing factor and hemagglutinins (author's transl)].
    Sato Y
    Tanpakushitsu Kakusan Koso; 1976 Nov; Suppl():164-83. PubMed ID: 194282
    [No Abstract]   [Full Text] [Related]  

  • 58. Elevation of levels of IgE antibody to tetanus toxin in individuals vaccinated with diphtheria-pertussis-tetanus vaccine.
    Matuhasi T; Ikegami H
    J Infect Dis; 1982 Aug; 146(2):290. PubMed ID: 7108275
    [No Abstract]   [Full Text] [Related]  

  • 59. ADP-ribosylation activity in pertussis vaccines and its relationship to the in vivo histamine-sensitisation test.
    Gomez SR; Yuen CT; Asokanathan C; Douglas-Bardsley A; Corbel MJ; Coote JG; Parton R; Xing DK
    Vaccine; 2007 Apr; 25(17):3311-8. PubMed ID: 17287049
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccines.
    Seubert A; D'Oro U; Scarselli M; Pizza M
    Expert Rev Vaccines; 2014 Oct; 13(10):1191-204. PubMed ID: 25183193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.